[go: up one dir, main page]

BRPI1006215A2 - " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo " - Google Patents

" anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "

Info

Publication number
BRPI1006215A2
BRPI1006215A2 BRPI1006215A BRPI1006215A BRPI1006215A2 BR PI1006215 A2 BRPI1006215 A2 BR PI1006215A2 BR PI1006215 A BRPI1006215 A BR PI1006215A BR PI1006215 A BRPI1006215 A BR PI1006215A BR PI1006215 A2 BRPI1006215 A2 BR PI1006215A2
Authority
BR
Brazil
Prior art keywords
antibody
immunoconjugate
inhibiting
nucleic acid
host cell
Prior art date
Application number
BRPI1006215A
Other languages
English (en)
Inventor
Schaefer Gabriele
Fuh Germaine
Haber Lauric
X Sliwkowski Mark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI1006215A2 publication Critical patent/BRPI1006215A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
BRPI1006215A 2009-03-20 2010-03-19 " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo " BRPI1006215A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21056209P 2009-03-20 2009-03-20
PCT/US2010/028023 WO2010108127A1 (en) 2009-03-20 2010-03-19 Bispecific anti-her antibodies

Publications (1)

Publication Number Publication Date
BRPI1006215A2 true BRPI1006215A2 (pt) 2019-09-24

Family

ID=42111063

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006215A BRPI1006215A2 (pt) 2009-03-20 2010-03-19 " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "

Country Status (27)

Country Link
US (4) US20120121596A1 (pt)
EP (2) EP3088420A1 (pt)
JP (2) JP5624114B2 (pt)
KR (3) KR101362522B1 (pt)
CN (2) CN104447995A (pt)
AR (1) AR075896A1 (pt)
AU (1) AU2010226453B2 (pt)
BR (1) BRPI1006215A2 (pt)
CA (1) CA2755640C (pt)
CL (1) CL2011002304A1 (pt)
CO (1) CO6430487A2 (pt)
CR (1) CR20110496A (pt)
EC (1) ECSP11011338A (pt)
ES (1) ES2572728T3 (pt)
HK (1) HK1205155A1 (pt)
IL (2) IL214827A (pt)
MA (1) MA33198B1 (pt)
MX (1) MX2011009729A (pt)
MY (1) MY152068A (pt)
NZ (1) NZ594665A (pt)
PE (1) PE20120539A1 (pt)
RU (2) RU2504553C2 (pt)
SG (2) SG174378A1 (pt)
TW (3) TWI461211B (pt)
UA (1) UA106070C2 (pt)
WO (1) WO2010108127A1 (pt)
ZA (1) ZA201106127B (pt)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
US8114967B2 (en) 2007-03-27 2012-02-14 Sea Lane Biotechnologies Llc Constructs and libraries comprising antibody surrogate light chain sequences
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
MX2010009669A (es) * 2008-03-06 2010-09-22 Genentech Inc Terapia de combinacion con antagonistas de c-met y egfr.
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
CN102822201B (zh) 2009-12-22 2014-09-24 罗切格利卡特公司 抗her3抗体及其用途
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
BR112012027001A2 (pt) 2010-04-23 2016-07-19 Genentech Inc produção de proteínas heteromultiméricas
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX348637B (es) * 2010-11-01 2017-06-22 Symphogen As Anticuerpos y composiciones anti-her3.
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012071648A1 (en) * 2010-11-30 2012-06-07 London Health Sciences Centre Research Inc. Egfr antagonist for the treatment of heart disease
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
WO2012156532A1 (en) 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
WO2013016714A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
RU2614254C2 (ru) 2011-08-31 2017-03-24 Дженентек, Инк. Диагностические маркеры
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
KR20140066783A (ko) 2011-09-30 2014-06-02 제넨테크, 인크. 종양 또는 종양 세포에서의 상피 또는 중간엽 표현형 및 egfr 키나제 억제제에 대한 반응의 진단 메틸화 마커
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
ES2745684T3 (es) 2011-11-23 2020-03-03 Medimmune Llc Moléculas de unión específicas para HER3 y usos de las mismas
KR20140098834A (ko) 2011-11-30 2014-08-08 제넨테크, 인크. 암에서의 erbb3 돌연변이
WO2013084147A2 (en) * 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
AU2013240261A1 (en) * 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9527913B2 (en) * 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
KR102023401B1 (ko) 2012-05-10 2019-11-04 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
HRP20250525T1 (hr) 2012-05-18 2025-06-20 Genentech, Inc. Visokokoncentrirane formulacije monoklonskog protutijela
CN104379604A (zh) * 2012-05-24 2015-02-25 弗·哈夫曼-拉罗切有限公司 多特异性抗体
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP3401337A1 (en) 2012-09-25 2018-11-14 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
PT2900694T (pt) 2012-09-27 2018-11-13 Merus Nv Anticorpos de igg biespecíficos como ativadores de células t
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
MX2015005756A (es) 2012-11-08 2015-09-16 Hoffmann La Roche Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4.
RU2015127037A (ru) * 2012-12-07 2017-01-11 Дзе Дженерал Хоспитал Корпорейшн Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения
US9180185B2 (en) * 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
HK1218930A1 (zh) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
CN105246508A (zh) * 2013-03-14 2016-01-13 基因泰克公司 Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
KR102190220B1 (ko) * 2013-05-29 2020-12-14 삼성전자주식회사 타겟 특이적 세포막 단백질 제거용 조성물
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
NZ720161A (en) 2013-11-04 2022-07-29 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
ES2865196T3 (es) 2013-11-07 2021-10-15 Inst Nat Sante Rech Med Anticuerpos anti-HER3 humana alostéricos de neuregulina
JP7325166B2 (ja) 2013-12-20 2023-08-14 ジェネンテック， インコーポレイテッド 二重特異性抗体
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
CA2941030C (en) * 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
ES3006007T3 (en) 2014-02-28 2025-03-17 Merus Nv Antibody that binds erbb-2 and erbb-3
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
KR20160137599A (ko) 2014-03-24 2016-11-30 제넨테크, 인크. C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
EP3126384B1 (en) * 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
EP3140392B1 (en) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
KR102223502B1 (ko) 2014-05-09 2021-03-05 삼성전자주식회사 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
CN106255705B (zh) 2014-05-14 2021-01-08 豪夫迈·罗氏有限公司 结合HER3β-发夹和HER2域II的HER3/HER2双特异性抗体
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN114133456A (zh) * 2014-07-21 2022-03-04 德里尼亚公司 选择性地活化调节性t细胞用于治疗自身免疫病的分子
KR102259232B1 (ko) * 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
KR20170063755A (ko) 2014-09-26 2017-06-08 마크로제닉스, 인크. Cd19 및 cd3에 결합할 수 있는 이중-특이적 1가 디아바디, 및 그것의 사용
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
CN107207615A (zh) 2014-11-05 2017-09-26 得克萨斯州大学系统董事会 基因修饰的免疫效应细胞和用于扩增免疫效应细胞的工程化细胞
WO2016073629A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
EP4491195A3 (en) * 2014-12-22 2025-04-02 SystImmune, Inc. Bispecific tetravalent antibodies and methods of makiing and using thereof
CA2974807A1 (en) 2015-01-26 2016-08-04 Macrogenics, Inc. Multivalent molecules comprising dr5-binding domains
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3313887A2 (en) 2015-06-26 2018-05-02 MAB Discovery GmbH Monoclonal anti-il-1racp antibodies
EA201890028A1 (ru) 2015-07-10 2018-08-31 Мерус Н.В. Антитело, связывающее cd3 человека
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
CR20200423A (es) 2015-07-30 2021-01-20 Macrogenics Inc Moléculas de unión a pd-1 y métodos de uso de las mismas (divisional 2018-0062)
HK1251475A1 (zh) 2015-10-08 2019-02-01 Macrogenics, Inc. 用於癌症治疗的联合疗法
EP3365373B1 (en) 2015-10-23 2021-03-10 Merus N.V. Binding molecules that inhibit cancer growth
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
BR112018011781A2 (pt) 2015-12-14 2018-12-04 Macrogenics, Inc. molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
UY37127A (es) 2016-02-17 2017-08-31 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
CA3011949A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
GEAP202214922A (en) 2016-04-15 2022-02-10 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US10167342B2 (en) 2016-08-29 2019-01-01 Fazel Shokri Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
EP3526247A4 (en) * 2016-10-16 2021-04-14 Cantargia AB Anti-il1-rap antibodies
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
IL267589B2 (en) 2016-12-23 2024-11-01 Macrogenics Inc Adam9-binding molecules, and methods of use thereof
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
WO2018159582A1 (ja) 2017-02-28 2018-09-07 学校法人近畿大学 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法
KR102905513B1 (ko) 2017-03-31 2026-01-02 메뤼스 엔.페. NRG1 융합 유전자를 가지는 세포를 치료하기 위한 ErbB-2 및 ErbB-3 결합 이중특이적 항체
SG11201908833TA (en) 2017-03-31 2019-10-30 Merus Nv Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
FI3665198T3 (fi) 2017-08-09 2025-04-25 Merus Nv EGFR:ää ja cMET:tä sitovia vasta-aineita
FI3684813T3 (fi) 2017-09-19 2026-01-12 Mab Discovery Gmbh Agonistisia CD40-vasta-aineita
EP3717008A1 (en) 2017-12-01 2020-10-07 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
AU2018385409A1 (en) 2017-12-12 2020-07-02 Macrogenics Inc. Bispecific CD 16-binding molecules and their use in the treatment of disease
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
KR20210009421A (ko) 2018-06-14 2021-01-26 바이오아트라, 엘엘씨 다중 특이적 항체 구조체
BR112021005246A2 (pt) 2018-09-20 2021-06-15 Daiichi Sankyo Company, Limited agente terapêutico, e, método de tratamento para câncer
US11873338B2 (en) 2018-12-20 2024-01-16 Merus N.V. CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
PE20211294A1 (es) 2018-12-21 2021-07-20 Hoffmann La Roche Anticuerpo que se une a vegf y a il-1beta y metodos de utilizacion
AU2020221649B2 (en) 2019-02-14 2025-03-27 Merus N.V. Producing compositions comprising two or more antibodies.
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
CA3130248A1 (en) 2019-02-14 2020-08-20 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3.
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
US12392777B2 (en) 2019-04-02 2025-08-19 National Research Council Of Canada Antibody variants with pH-dependent antigen binding for selective targeting of solid tumors
AR118898A1 (es) 2019-05-09 2021-11-10 Merus Nv Dominios variantes para multimerizar proteínas y su separación
MX2022002096A (es) 2019-08-19 2022-03-17 Merus Nv Tratamiento del cancer con una combinacion de un anticuerpo que se une al receptor 5 acoplado a la proteina g que contiene repeticiones ricas en leucina (lgr5) y al receptor del factor de crecimiento epidermico (egfr) y un inhibidor de topoisomerasa i.
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
US20220057383A1 (en) * 2019-12-19 2022-02-24 Johnson & Johnson Consumer Inc. Use of biomarkers to evaluate the efficacy of a composition in reducing the effects of cancer therapeutics on skin
CN114945596A (zh) 2020-01-29 2022-08-26 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法
MX2022010228A (es) 2020-02-21 2022-09-19 Macrogenics Inc Moleculas de union a cd137 y usos de las mismas.
WO2021198034A1 (en) 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Antibody that binds to vegf and pdgf-b and methods of use
KR20230005281A (ko) 2020-04-24 2023-01-09 메뤼스 엔.페. Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
WO2022010798A1 (en) 2020-07-06 2022-01-13 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
CA3193163A1 (en) 2020-09-04 2022-03-10 F. Hoffmann-La Roche Ag Antibody that binds to vegf-a and ang2 and methods of use
EP4225899A4 (en) * 2020-10-07 2025-10-08 Tatum Bioscience Inc LIVE BIOTHERAPEUTIC AGENTS SECRETING SYNTHETIC BACTERIOPHAGES IN THE TREATMENT OF CANCER
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
TW202237656A (zh) 2020-12-15 2022-10-01 荷蘭商美勒斯公司 利用結合ｌｇｒ５與ｅｇｆｒ之抗體治療癌症
WO2022131918A1 (en) 2020-12-18 2022-06-23 Merus N.V. Antibody composition
JP2024523001A (ja) 2021-06-03 2024-06-25 メルス ナムローゼ フェンノートシャップ 新たなｎｒｇ１融合体、融合接合部及びそれらを検出するための方法
CN118302192A (zh) * 2021-10-03 2024-07-05 西雅图免疫公司 治疗癌症的方法及其药物组合物
CN118055949A (zh) 2021-10-06 2024-05-17 美勒斯公司 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
TW202428613A (zh) 2022-09-21 2024-07-16 法商賽諾菲生物技術公司 人源化抗il-1r3抗體及使用方法
WO2024136658A1 (en) 2022-12-23 2024-06-27 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
IL321816A (en) 2022-12-28 2025-08-01 Merus Nv Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
CN121219016A (zh) 2023-06-02 2025-12-26 第一三共株式会社 抗-her3抗体-药物缀合物和rasg12c抑制剂的组合
TW202517675A (zh) * 2023-07-19 2025-05-01 大陸商映恩生物製藥（蘇州）有限公司 一種雙特異性抗體、其藥物偶聯物及其用途
WO2025103355A1 (zh) * 2023-11-14 2025-05-22 信达生物制药(苏州)有限公司 抗egfr和her3双特异性抗体-药物偶联物及其用途
WO2025140662A1 (en) * 2023-12-29 2025-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/her3 antibodies and uses thereof
WO2025244529A1 (en) 2024-05-22 2025-11-27 Merus N.V. Dosing regimen of an egfr binding and/or complement activating antibody

Family Cites Families (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4935341A (en) 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0412116B1 (en) 1988-04-18 1995-11-29 Oncogene Science, Inc. Detection of neu gene expression and products
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
EP1006194A3 (en) 1989-08-04 2008-07-02 Triton Biosciences Inc. C-erbB-2 external domain: GP75
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
JP2975679B2 (ja) 1989-09-08 1999-11-10 ザ・ジョーンズ・ホプキンス・ユニバーシティ ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化
DE68926248T2 (de) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
WO1993003741A1 (en) 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5288477A (en) 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
WO1994000136A1 (en) 1992-06-30 1994-01-06 Oncologix, Inc. A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
WO1993012220A1 (en) 1991-12-12 1993-06-24 Berlex Laboratories, Inc. RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1994009022A1 (en) 1992-10-09 1994-04-28 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
PT616812E (pt) 1993-03-24 2000-04-28 Berlex Biosciences Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0711565B1 (en) 1994-11-10 1998-08-26 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
GEP20012442B (en) 1996-04-12 2001-05-25 Warner Lambert Co Irreversible Inhibitors of Tyrosine Kinases
US5925519A (en) 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US6468547B1 (en) 1996-10-30 2002-10-22 Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
ATE371673T1 (de) 1996-11-27 2007-09-15 Genentech Inc Affinitätsreinigung von polypeptiden an einer protein a-matrix
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US20030171551A1 (en) 1997-01-31 2003-09-11 Joseph D. Rosenblatt Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US20020076695A1 (en) 1997-04-04 2002-06-20 Jeffrey S. Ross Methods for treating prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999019488A1 (en) 1997-10-15 1999-04-22 Children's Medical Center Corporation Novel human egf receptors and use thereof
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20020192211A1 (en) 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
CA2324494A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
SI1308455T1 (sl) 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
CA2332331A1 (en) 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
WO2000044225A1 (en) 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
HUP0201480A3 (en) 1999-05-14 2009-03-30 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
PT1189634E (pt) 1999-06-25 2007-06-06 Genentech Inc Tratamento de cancro da próstata com anticorpos anti-erbb2.
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
SI2283867T1 (sl) 1999-06-25 2014-07-31 Immunogen, Inc. Metode zdravljenja z majtanzinoidom konjugiranim protitelesom anti-ErbB
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
HU230586B1 (hu) 1999-06-25 2017-02-28 Genentech, Inc. Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
CA2383615A1 (en) 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
WO2001053354A2 (en) 2000-01-20 2001-07-26 Chiron Corporation Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
WO2001064246A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6767541B2 (en) 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
WO2001076630A1 (en) 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for rheumatoid arthritis
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
NZ523004A (en) 2000-05-15 2004-09-24 Pharmacia Italia S Aromatase inhibitors and monoclonal anti-HER2 antibodies having a synergistic or super-additive effect as an antitumour agent
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
SI1282443T1 (sl) 2000-05-19 2010-01-29 Genentech Inc Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
AU2001295002B2 (en) 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7005278B2 (en) 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
MX2008005896A (es) 2000-12-01 2009-03-03 Response Genetics Inc Metodo in vitro para predecir la sensibilidad de un tumor a un regimen quimioterapico.
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US20020142328A1 (en) 2000-12-01 2002-10-03 Danenberg Kathleen D. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
US20020076408A1 (en) 2000-12-08 2002-06-20 Buchsbaum Donald J. Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
JP4398644B2 (ja) * 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ＥｒｂＢ界面ペプチド擬態およびその使用方法
US20040138160A1 (en) 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
MXPA03010121A (es) 2001-05-08 2004-03-10 Merck Patent Gmbh Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
WO2003012072A2 (en) 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20030068318A1 (en) 2001-09-28 2003-04-10 O'brien Timothy Treatment of uterine serous papillary cancer
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20030096823A1 (en) 2001-11-16 2003-05-22 Beryl Asp Method for the treatment of cardiotoxicity induced by antitumor compounds
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030175845A1 (en) 2002-03-13 2003-09-18 Kalbag Suresh M. Use of sulfitolysis in high performance peptide mapping
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
EP1492568A1 (en) 2002-04-08 2005-01-05 SmithKline Beecham Corporation Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
EP1500698B1 (en) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
WO2003087131A2 (en) 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
ITTO20020340A1 (it) 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
US20030202973A1 (en) 2002-04-29 2003-10-30 Dr. George Pieczenik Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
JP5069843B2 (ja) 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
CN1703243B (zh) 2002-10-10 2011-05-04 默克专利有限公司 针对erb-b1受体的药物组合物
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004048525A2 (en) 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004087207A2 (en) 2003-03-27 2004-10-14 Georgetown University Method for inducing apoptosis and aneuploidy regression in cancer cells
WO2005000900A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
MXPA06001989A (es) 2003-08-18 2006-05-17 Pfizer Prod Inc Programa de dosificacion para un nuevo agente anticanceroso.
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
HRP20130440T1 (en) 2004-04-13 2013-06-30 F. Hoffmann - La Roche Ag Anti-p-selectin antibodies
US8124085B2 (en) 2004-05-05 2012-02-28 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US7521541B2 (en) * 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
JP2008526205A (ja) 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
RU2438705C2 (ru) 2005-01-21 2012-01-10 Дженентек, Инк. Введение фиксированных доз her-антител
JP2008531557A (ja) * 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101321784A (zh) * 2005-10-11 2008-12-10 埃博灵克斯股份有限公司 针对egfr和igf－ir的纳米抗体tm和多肽
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2631727T3 (es) 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
EP2138511A1 (en) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
AU2010226453B2 (en) * 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
JP5587975B2 (ja) 2009-04-07 2014-09-10 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
CN105999263B (zh) 2009-11-13 2021-06-29 第一三共欧洲有限公司 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
CN102822201B (zh) 2009-12-22 2014-09-24 罗切格利卡特公司 抗her3抗体及其用途
JP2012016491A (ja) 2010-07-08 2012-01-26 Panasonic Electric Works Co Ltd 往復式電気かみそり
AU2013240261A1 (en) * 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
EP2971108A1 (en) * 2013-03-14 2016-01-20 F. Hoffmann-La Roche AG Predicting response to egfr inhibitors

Also Published As

Publication number Publication date
ZA201106127B (en) 2014-03-26
EP3088420A1 (en) 2016-11-02
KR101362522B1 (ko) 2014-02-14
CN104447995A (zh) 2015-03-25
CL2011002304A1 (es) 2012-04-09
TWI461211B (zh) 2014-11-21
UA106070C2 (uk) 2014-07-25
AU2010226453A1 (en) 2011-09-08
IL214827A0 (en) 2011-11-30
KR20130080871A (ko) 2013-07-15
EP2408817B1 (en) 2016-03-16
CA2755640A1 (en) 2010-09-23
MX2011009729A (es) 2011-10-14
US20140056899A1 (en) 2014-02-27
RU2504553C2 (ru) 2014-01-20
US20140193414A1 (en) 2014-07-10
US9327035B2 (en) 2016-05-03
NZ594665A (en) 2013-08-30
HK1165809A1 (en) 2012-10-12
PE20120539A1 (es) 2012-05-12
ECSP11011338A (es) 2011-10-31
IL233563A0 (en) 2014-08-31
IL214827A (en) 2016-10-31
AR075896A1 (es) 2011-05-04
JP5624114B2 (ja) 2014-11-12
CN102356092B (zh) 2014-11-05
MY152068A (en) 2014-08-15
SG174378A1 (en) 2011-10-28
US20120121596A1 (en) 2012-05-17
TW201544123A (zh) 2015-12-01
RU2013146469A (ru) 2015-04-27
JP2014158481A (ja) 2014-09-04
MA33198B1 (fr) 2012-04-02
US20100255010A1 (en) 2010-10-07
KR20110117256A (ko) 2011-10-26
JP2012521196A (ja) 2012-09-13
ES2572728T3 (es) 2016-06-02
KR20150036824A (ko) 2015-04-07
TW201036637A (en) 2010-10-16
CA2755640C (en) 2018-05-22
WO2010108127A1 (en) 2010-09-23
HK1205155A1 (en) 2015-12-11
AU2010226453B2 (en) 2013-11-21
US8597652B2 (en) 2013-12-03
TW201438739A (zh) 2014-10-16
EP2408817A1 (en) 2012-01-25
SG10201402742YA (en) 2014-08-28
RU2011142281A (ru) 2013-04-27
CR20110496A (es) 2011-12-06
CN102356092A (zh) 2012-02-15
CO6430487A2 (es) 2012-04-30

Similar Documents

Publication Publication Date Title
BRPI1006215A2 (pt) " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI1006270A2 (pt) ''anticorpo anti a5b1, molécula de ácido nucleio isolado, célula hospedeira, método de produção de um anticorpo anti a5b1, imunoconjugado, composição farmacêutica, método de detecção de proteína a5b1, método de tratamento de um indivíduo e kit de detecção de a5b1
BR112012022210A2 (pt) anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
BRPI0922106A2 (pt) anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BR112012015255A2 (pt) "anticorpo, composição farmaceutica, uso de um anticorpo,método de tramento ,ácido nucleico, vetor de espressão, célula hospedeira e método de produção de um anticorpo recobinante"
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
BRPI0905752A2 (pt) "muteína de lipocalina da lágrima humana (htlc), molécula de ácido nucléico, célula hospedeira, composição farmacêutica, método para a produção de uma muteína de lipocalina da lágrima humana, método de tratamento de uma doença ou distúrbio e uso de uma mateína de lipocalina da lágrima humana"
BR112014021103A8 (pt) anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BRPI0812575A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos
BR112012024287A2 (pt) anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
IT1391619B1 (it) Metodo per l'individuazione, selezione e analisi di cellule tumorali
EP2456361A4 (en) SYSTEMS FOR CONTINUOUS ANALYTING MEASUREMENT AND SYSTEMS AND METHOD FOR THE IMPLEMENTATION THEREOF
EP2611927A4 (en) NEW INDIVIDUAL CHEMICAL UNITS AND METHOD FOR THE DISPOSAL OF OLIGONUCLEOTIDES
BR112015029788A2 (pt) hetero-multímero, construto de anticorpo isolado, ácido nucleico, célula hospedeira, método para preparar o hetero-multímero, composição farmacêutica, método para tratar uma doença, uso do hetero-multímero, uso de uma quantia terapêutica do hetero-multímero e método para reduzir a função efetora de um construto de anticorpo
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112012020373A2 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tata419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
BR112012010859A2 (pt) ''composto,formulação farmacêutica,processo de preparação de um composto,uso de um composto e método de tratamento ou profilaxia de distúrbio proliferativos celulares''
BR112014017518A8 (pt) anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
BRPI0816330A2 (pt) Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
BR112015010817A2 (pt) anticorpos anti-hemaglutinina, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
EP2591792A4 (en) COMPOSITION FOR NUCLEIC ACID DELIVERY, CARRIER COMPOSITION, PHARMACEUTICAL COMPOSITION COMPRISING THE NUCLEIC ACID DELIVERY OR SUPPORT COMPOSITION, AND NUCLEIC ACID DELIVERY METHOD
BR112014029274A2 (pt) anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira.
EP2412706A4 (en) NEW HYDROXAMATE DERIVATIVE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THEREWITH

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.